These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Developmental origins and emerging therapeutic opportunities for childhood cancer. Filbin M; Monje M Nat Med; 2019 Mar; 25(3):367-376. PubMed ID: 30842674 [TBL] [Abstract][Full Text] [Related]
6. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies. Knott MML; Hölting TLB; Ohmura S; Kirchner T; Cidre-Aranaz F; Grünewald TGP Cancer Metastasis Rev; 2019 Dec; 38(4):625-642. PubMed ID: 31970591 [TBL] [Abstract][Full Text] [Related]
7. Fusion Oncoproteins in Childhood Cancers: Potential Role in Targeted Therapy. Angione SDA; Akalu AY; Gartrell J; Fletcher EP; Burckart GJ; Reaman GH; Leong R; Stewart CF J Pediatr Pharmacol Ther; 2021; 26(6):541-555. PubMed ID: 34421403 [TBL] [Abstract][Full Text] [Related]
8. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662 [TBL] [Abstract][Full Text] [Related]
9. Emerging Targeted Therapy for Tumors with Kheder ES; Hong DS Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850 [TBL] [Abstract][Full Text] [Related]
10. Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy. Vellichirammal NN; Chaturvedi NK; Joshi SS; Coulter DW; Guda C Cancer Lett; 2021 Feb; 499():24-38. PubMed ID: 33248210 [TBL] [Abstract][Full Text] [Related]
12. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical. Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228 [TBL] [Abstract][Full Text] [Related]
13. On the right TRK: from oncogene discovery to cancer therapeutics. Barbacid M Ann Oncol; 2019 Nov; 30 Suppl 8(Suppl 8):viii3-viii4. PubMed ID: 32223936 [No Abstract] [Full Text] [Related]
14. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Roskoski R Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216 [TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic ALK: a promising strategy for cancer treatment. Grande E; Bolós MV; Arriola E Mol Cancer Ther; 2011 Apr; 10(4):569-79. PubMed ID: 21474455 [TBL] [Abstract][Full Text] [Related]
16. New approaches to therapeutic drug development for childhood cancers. Campbell K; Ma C; DuBois SG Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026 [TBL] [Abstract][Full Text] [Related]
17. PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models. Yang J; Li Q; Noureen N; Fang Y; Kurmasheva R; Houghton PJ; Wang X; Zheng S Nucleic Acids Res; 2021 Jan; 49(D1):D1321-D1327. PubMed ID: 32810235 [TBL] [Abstract][Full Text] [Related]
18. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target. Laxmi A; Gupta P; Gupta J Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182 [TBL] [Abstract][Full Text] [Related]
19. TRK inhibitors in TRK fusion-positive cancers. Drilon A Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426 [TBL] [Abstract][Full Text] [Related]